Tianjin Tianyao Pharmaceuticals Co Ltd Cash Flow-to-Debt Ratio
Tianjin Tianyao Pharmaceuticals Co Ltd cash flow-to-debt ratio. Tianjin Tianyao Pharmaceuticals Co Ltd (600488) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of CN¥13.19 Million could theoretically repay 0% of its total liabilities (CN¥1.85 Billion) in one year. Check cash flow quality index of Tianjin Tianyao Pharmaceuticals Co Ltd to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Tianjin Tianyao Pharmaceuticals Co Ltd (2000–2024)
Cash flow-to-debt ratio of Tianjin Tianyao Pharmaceuticals Co Ltd from 2000 to 2024. Historical debt coverage capacity for Tianjin Tianyao Pharmaceuticals Co Ltd across 25 annual periods. Check Tianjin Tianyao Pharmaceuticals Co Ltd (600488) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Tianjin Tianyao Pharmaceuticals Co Ltd Cash Flow-to-Debt Ratio by Year (2000–2024)
Tianjin Tianyao Pharmaceuticals Co Ltd cash flow-to-debt ratio by year from 2000 to 2024. Year-by-year debt coverage analysis for Tianjin Tianyao Pharmaceuticals Co Ltd. For the full cash flow conversion analysis, see Tianjin Tianyao Pharmaceuticals Co Ltd (600488) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.31x | CN¥569.37 Million | CN¥1.81 Billion | ▼ -4.1% |
| 2023 | 0.33x | CN¥783.01 Million | CN¥2.39 Billion | ▲ +45.3% |
| 2022 | 0.23x | CN¥653.52 Million | CN¥2.90 Billion | ▲ +80.0% |
| 2021 | 0.13x | CN¥316.89 Million | CN¥2.53 Billion | ▼ -13.2% |
| 2020 | 0.14x | CN¥346.88 Million | CN¥2.40 Billion | ▼ -12.4% |
| 2019 | 0.16x | CN¥279.37 Million | CN¥1.70 Billion | ▲ +32.2% |
| 2018 | 0.12x | CN¥189.27 Million | CN¥1.52 Billion | ▲ +1865.8% |
| 2017 | -0.01x | CN¥-8.15 Million | CN¥1.15 Billion | ▼ -105.7% |
| 2016 | 0.12x | CN¥63.32 Million | CN¥511.21 Million | ▼ -44.1% |
| 2015 | 0.22x | CN¥129.50 Million | CN¥584.42 Million | ▼ -37.9% |
| 2014 | 0.36x | CN¥178.76 Million | CN¥501.34 Million | ▲ +231.3% |
| 2013 | 0.11x | CN¥84.55 Million | CN¥785.64 Million | ▲ +489.2% |
| 2012 | 0.02x | CN¥13.23 Million | CN¥724.13 Million | ▼ -83.0% |
| 2011 | 0.11x | CN¥78.47 Million | CN¥729.86 Million | ▲ +18.6% |
| 2010 | 0.09x | CN¥116.82 Million | CN¥1.29 Billion | ▼ -77.8% |
| 2009 | 0.41x | CN¥435.13 Million | CN¥1.07 Billion | ▲ +98.5% |
| 2008 | 0.21x | CN¥219.31 Million | CN¥1.07 Billion | ▲ +8.1% |
| 2007 | 0.19x | CN¥162.33 Million | CN¥854.65 Million | ▲ +404.7% |
| 2006 | 0.04x | CN¥50.72 Million | CN¥1.35 Billion | ▲ +132.3% |
| 2005 | -0.12x | CN¥-108.87 Million | CN¥933.43 Million | ▼ -157.2% |
| 2004 | 0.20x | CN¥110.30 Million | CN¥541.10 Million | ▲ +198.1% |
| 2003 | 0.07x | CN¥45.77 Million | CN¥669.25 Million | ▼ -4.2% |
| 2002 | 0.07x | CN¥45.28 Million | CN¥634.50 Million | ▼ -58.4% |
| 2001 | 0.17x | CN¥71.87 Million | CN¥419.39 Million | ▲ +21.5% |
| 2000 | 0.14x | CN¥41.06 Million | CN¥291.03 Million | — |